Warrants for 456,427 shares are excluded from a reported stake in Quince Therapeutics (QNCX).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported an 8.4% beneficial ownership in Quince Therapeutics (QNCX), totaling 912,853 common shares. This stake excludes warrants for 456,427 common shares, as they are not yet exercisable due to a pending "Triggering Event" related to the LAM-001 Phase 2 trial.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.